Trending...
- T. Jones Group's Cameron Jones Serves as Judge for the 2026 CHBA National Awards for Housing Excellence
- $29.8 Million Record Setting Q1 with Boosted Annual Guidance to $160 Million for Expanding Pre-Owned Boat Dealer: Off The Hook YS, Inc. N Y S E: OTH
- SRK Collective Media Group Launches with a Modern Approach to Media, Authority Building, and Cultural Visibility
MORRISVILLE, N.C.--(BUSINESS WIRE)--Life Edit Therapeutics Inc., an ElevateBio company focused on next-generation genome editing technologies and therapeutics, today announced the appointment of Joy A. Cavagnaro, Ph.D., DABT, Fellow ATS, RAC, FRAPS, to its Scientific Advisory Board (SAB). Dr. Cavagnaro is an internationally recognized expert in science-based regulatory strategies and translation of research to preclinical and product development, with an emphasis on genetic medicines.
"We are thrilled to welcome Joy to our Scientific Advisory Board as we rapidly advance our gene editing platform to harness the vast potential of our novel nucleases and base editors as therapeutics," said Mitchell Finer, Ph.D., Chief Executive Officer, Life Edit Therapeutics and President, R&D, ElevateBio. "Joy's expertise in drug discovery and development will complement our esteemed Scientific Advisory Board slate, and collectively our advisors will continue to help Life Edit and our partners further therapeutic programs to address the tremendous unmet needs of genetically-defined diseases."
Joy A. Cavagnaro, Ph.D., DABT, Fellow ATS, RAC, FRAPS, has more than 40 years of experience in the biotechnology industry and is the President and Founder of Access BIO, where she consults globally on science-based preclinical development strategies. She served at the United States Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER) and was appointed to Senior Biomedical Research Service. Dr. Cavagnaro was also the past Chair of the Regulatory Affairs Professional Society (RAPS), President of the National Capital Area Chapter of the Society of Toxicology (SOT), and recipient of the Society's 2019 Arnold J. Lehman Award. Later this year, the American College of Toxicology is expected to recognize Dr. Cavagnaro with the Distinguished Scientist Award in Toxicology. In addition, Dr. Cavagnaro has co-authored numerous white papers, articles, and book chapters related to various aspects of preclinical safety assessment. She received her Ph.D. in Biochemistry from the University of North Carolina at Chapel Hill, followed by post-graduate work at Duke University and Boston University Medical Centers.
More on ncarol.com
"Life Edit holds one of the largest and most diverse arrays of novel RNA-guided nucleases and base editors that offers flexible editing and unprecedented access to the genome," said Joy Cavagnaro, Ph.D., DABT, Fellow ATS, RAC, FRAPS. "This powerful technology platform unlocks enormous potential for the development of novel therapeutics, and I look forward to working with the company as they continue to advance their gene editing platform and own internal pipeline of in vivo gene therapies for patients in need."
About Life Edit Therapeutics Inc.
Life Edit Therapeutics, an ElevateBio company, is a next-generation genome editing company that has built a highly innovative platform with one of the world's largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors. The platform allows Life Edit to target any genomic sequence and develop novel human therapeutics for the most challenging genetic diseases by enabling ex vivo engineering for cell therapies and regenerative medicines and in vivo delivery of gene therapies. In addition to developing its own pipeline of cell and gene therapies, Life Edit Therapeutics will continue to strengthen its platform of genome-editing enzymes, provide gene-editing expertise to strategic partners, and form other third-party partnerships to discover and develop new therapies. For more information visit lifeeditinc.com or on LinkedIn or Twitter.
More on ncarol.com
Contacts
Investor Contact:
Catherine Hu
chu@elevate.bio
Life Edit Media Contact:
Courtney Heath
courtney@scientpr.com
"We are thrilled to welcome Joy to our Scientific Advisory Board as we rapidly advance our gene editing platform to harness the vast potential of our novel nucleases and base editors as therapeutics," said Mitchell Finer, Ph.D., Chief Executive Officer, Life Edit Therapeutics and President, R&D, ElevateBio. "Joy's expertise in drug discovery and development will complement our esteemed Scientific Advisory Board slate, and collectively our advisors will continue to help Life Edit and our partners further therapeutic programs to address the tremendous unmet needs of genetically-defined diseases."
Joy A. Cavagnaro, Ph.D., DABT, Fellow ATS, RAC, FRAPS, has more than 40 years of experience in the biotechnology industry and is the President and Founder of Access BIO, where she consults globally on science-based preclinical development strategies. She served at the United States Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER) and was appointed to Senior Biomedical Research Service. Dr. Cavagnaro was also the past Chair of the Regulatory Affairs Professional Society (RAPS), President of the National Capital Area Chapter of the Society of Toxicology (SOT), and recipient of the Society's 2019 Arnold J. Lehman Award. Later this year, the American College of Toxicology is expected to recognize Dr. Cavagnaro with the Distinguished Scientist Award in Toxicology. In addition, Dr. Cavagnaro has co-authored numerous white papers, articles, and book chapters related to various aspects of preclinical safety assessment. She received her Ph.D. in Biochemistry from the University of North Carolina at Chapel Hill, followed by post-graduate work at Duke University and Boston University Medical Centers.
More on ncarol.com
- New from Regal House Publishing, Minerva, a girl raised in a politically divided country
- Mutant-Fueled Bio-Cyberpunk Shooter HoverGrease 2 Launches May 22
- Triple-Digit Growth, OTCQX Market Upgrade and a Rapidly Expanding Specialty Healthcare Platform: Cardiff Lexington Corporation: Stock Symbol: CDIX
- XRPPower Continues Strengthening Its Global AI-Powered Blockchain Ecosystem
- Lick Introduces Pineapple Flavored Massage Oil — A Tropical Date Night Favorite Available on Amazon
"Life Edit holds one of the largest and most diverse arrays of novel RNA-guided nucleases and base editors that offers flexible editing and unprecedented access to the genome," said Joy Cavagnaro, Ph.D., DABT, Fellow ATS, RAC, FRAPS. "This powerful technology platform unlocks enormous potential for the development of novel therapeutics, and I look forward to working with the company as they continue to advance their gene editing platform and own internal pipeline of in vivo gene therapies for patients in need."
About Life Edit Therapeutics Inc.
Life Edit Therapeutics, an ElevateBio company, is a next-generation genome editing company that has built a highly innovative platform with one of the world's largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors. The platform allows Life Edit to target any genomic sequence and develop novel human therapeutics for the most challenging genetic diseases by enabling ex vivo engineering for cell therapies and regenerative medicines and in vivo delivery of gene therapies. In addition to developing its own pipeline of cell and gene therapies, Life Edit Therapeutics will continue to strengthen its platform of genome-editing enzymes, provide gene-editing expertise to strategic partners, and form other third-party partnerships to discover and develop new therapies. For more information visit lifeeditinc.com or on LinkedIn or Twitter.
More on ncarol.com
- FutureLot Powers ADU Wizard for Massachusetts Clean Energy Center's Statewide ADU Resource Center
- ICT Innovations Releases ICTPBX Community Edition as Open Source Under Mozilla Public License 2.0
- BundleSpy.com lanunches new AI search report
- Maryland Personal Injury Firm Earns National Recognition in 2026 ELA Awards
- Robert J. Bradshaw's AYE is a Gripping Dual Reality Thriller Exploring the Increasingly Blurred Line Between Humanity and Technology
Contacts
Investor Contact:
Catherine Hu
chu@elevate.bio
Life Edit Media Contact:
Courtney Heath
courtney@scientpr.com
Filed Under: Business
0 Comments
Latest on ncarol.com
- Sunday Best Winner Tasha Page-Lockhart Headlines A'Leurer's 1-Year Anniversary Celebration in Greensboro
- CAPO Supply Announces Opening of Second Location in New Castle, Pennsylvania
- $224 Billion Growing Market in Life Settlements Presents Major Opportunity for New Policy Acquisition Business Plan: DLT Resolution Stock Symbol: DLTI
- New from Regal House Publishing, Margery and Me, based on the true story of psychic Margery Crandon
- Fyt-02 Launches on Kickstarter The Smart Sensor That Turns Any Chair Into a Posture & Movement Track
- YieldOMega Launches $DOUB Airdrop Campaign Ahead of TimeCurve Launch
- Kaltra Expands Microchannel Water Coil Line for U.S. HVAC Market With New Corrosion-Resistant Tube Technology
- Collectibles EvoRelic Celebrates Stellar 4.8-Star Customer Rating
- Phoenix Hip-hop Artist Rhymi Hits 23k Monthly Listeners 12 Days After Album Release
- Pediatrician Launches "Confessions of a Detective Doctor" Children's Book Series
- Integrated Maintenance Platforms Are Transforming Aircraft Operations
- T. Jones Group's Cameron Jones Serves as Judge for the 2026 CHBA National Awards for Housing Excellence
- Derek Advanced Tracking Systems Revolutionizes Asset Monitoring with Advanced Technology
- The AI Direction Deficit: TripleTen Study Finds Staff Get Told to Use AI — But Not Trained to Use It
- $29.8 Million Record Setting Q1 with Boosted Annual Guidance to $160 Million for Expanding Pre-Owned Boat Dealer: Off The Hook YS, Inc. N Y S E: OTH
- All About Technology Celebrates 25 Years of Bridging Detroit's Digital Divide
- iatroX surpasses 500,000 clinical queries and expands specialist exam coverage
- Inside-Out Hollywood: The Relentless Rise of Joseph Nybyk (AKA Joseph Neibich)
- Husband-and-Wife Photography Team Brings Personal Approach to Families Across the Triangle
- SRK Collective Media Group Launches with a Modern Approach to Media, Authority Building, and Cultural Visibility